CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 31 enrolled
Drug / intervention
Oliceridine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05465226
NCT05465226Phase 4Completed

A pRospective, Case-controlled Evaluation of oLIceridine for Moderate or sEVEre Pain in Patients With Acute Burn Injuries. (RELIEVE)

University of Tennessee·interventional·Posted Jul 19, 2022·Updated Oct 26, 2023

In Brief

A Phase 4 clinical trial evaluating Oliceridine and Historical opioid use for Acute Pain and 4 related conditions. Completed, enrolled 31 participants across 1 site.

Detailed Summary

Pain after acute burn injury is complex with much still not understood. The primary mechanism is believed to be nociceptive, but is interwoven with aspects of somatogenic, neuropathic, and psychogenic pathways. As such, opioid receptor agonists are an essential component for pain management after burn injury. The majority of wound care and dressing changes are completed in non-intubated patients and rates of respiratory depression concerning. Oliceridine is a biased, selective MOR agonist approved for treatment of acute pain. To date there is no literature of use in patients with burn injuries. While it should be effective, efficacy and the potential for reduced adverse events need to be quantified. Current practice and guidelines, plead for better analgesia for patients with burn injuries.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2023202420252026
First PostedJul 19, 2022
Enrollment StartApr 1, 2023
Primary CompletionSep 30, 2023
Study CompletionOct 24, 2023
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 4.0 years ago

Interventions

Oliceridinedrug

see arm description

Historical opioid usedrug

Historical matched, control group in 2:1 ratio